Cetuximab is an active treatment of metastatic and chemorefractory thymoma(371 views) Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L
Frontiers In Bioscience (ISSN: 1093-9946, 1093-4715), 2007 Jan 1; 12(2): 757-761.
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Naples, Italy
Department of Pathology, Regina Elena Cancer Institute, Rome, Italy
Diagnostic Imaging and Radiotherapy Department, Federico II University, Naples, Italy
Experimental Pharmacology Unit, Department of Experimental Oncology, National Institute of Tumours, Naples, Italy
References: Bianco, R., Daniele, G., Ciardiello, F., Tortora, G., Monoclonal antibodies targeting the epidermal growth factor receptor (2005) Curr Drug Targets, 6, pp. 275-28
Caponigro, F., Formato, R., Caraglia, M., Normanno, N., Iaffaioli, R.V., Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors (2005) Curr Opin Oncol, 17, pp. 212-217
Saltz, L.B., Meropol, N.J., Loehrer Sr., P.J., Needle, M.N., Kopit, J., Mayer, R.J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor (2004) J Clin Oncol, 22, pp. 1201-1208
Gilhus, N.B., Jones, M., Turley, H., Gatter, K.C., Nagvekar, N., Newsom-Davis, J., Willcox, N., Oncogene proteins and proliferation antigens in thymomas: Increased expression of epidermal growth factor receptor and Ki67 antigen (1995) J Clin Pathol, 48, pp. 447-455
Henley, J.D., Koukoulis, G.K., Loehrer Sr., P.J., Epidermal growth factor receptor expression in invasive thymoma (2002) J Cancer Res Clin Oncol, 128, pp. 167-170
Rosai, J., Sobin, L.H., Histological typing of tumours of the thymus (1999) World Health Organization, International Histological Classification of Tumours, , Springer Verlag: Berlin Heidelberg New York 2nd edition
Travis, W.D., Brambilla, E., Mueller-Hermelink, H.K., Harris, C.C., Tumours of the Lung, Pleura, Thymus and Heart (2004) World Health Organization International Classification of Tumour, , IARC Press Lyon
Masaoka, A., Monden, Y., Nakahara, K., Tanioka, T., Follow-up study of thymomas with special reference to their clinical stages (1981) Cancer, 48, pp. 2485-2492
Palmieri, G., Montella, L., Martinetti, A., Muto, P., Di Vizio, D., De Chiara, A., Lastoria, S., Somatostatin analogs and prednisone in advanced refractory thymic tumors (2002) Cancer, 94, pp. 1414-1420
Ströbel, P., Hartmann, M., Jacok, A., Mikesch, K., Brink, I., Dirnhofer, S., Marx, A., Thymic Carcinoma with Overexpression of Mutated KIT and the Response to Imatinib (2004) N Engl J Med, 25, pp. 2625-2626
Hayashi, Y., Ishii, N., Obayashi, C., Jinnai, K., Hanioka, K., Imai, Y., Itoh, H., Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21 (1995) Virchows Arch, 426, pp. 43-50
Ionescu, D.N., Sasatomi, E., Cieply, K., Nola, M., Dacic, S., Protein expression and gene amplification of epidermal growth factor receptor in thymomas (2005) Cancer, 103, pp. 630-636
Avril, N.B., Weber, W.A., Monitoring response to treatment in patients utilizing PET (2005) Radiol Clin North Am, 43, pp. 189-204
Kelloff, G.J., Hoffman, J.M., Johnson, B., Scher, H.I., Siegel, B.A., Cheng, E.Y., Cheson, B.D., Sullivan, D.C., Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development (2005) Clin Cancer Res, 11, pp. 2785-2808
Price, P., Jones, T., Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group (1995) Eur J Cancer, 31 A, pp. 1924-1927
S.N. Reske, J. Kotzerke: FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, Onko-PET III, 21 July and 19 September 2000. Eur J Nuct Med 28:1707-23 (2001)UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-34249818183&partnerID=40&md5=d6c564581d91dec052100fb8ebd3b75a
Cetuximab is an active treatment of metastatic and chemorefractory thymoma
Advanced chemorefractory thymic epithelial tumors still represent a challenge in clinical oncology. A rationale-based therapeutic approach targeting a key pathway should represent the ideal solution in a neoplasm that can over-express Epidermal Growth Factor Receptor (EGFR) in the epithelial component. On the basis of these considerations, two patients with metastatic heavily pretreated disease were evaluated for EGFR expression in the primitive tumor, being considered this data as a basis for an anti EGFR treatment with the monoclonal antibody cetuximab which targets EGFR. A strong EGFR expression was revealed by immunohistochemistry in the two cases considered, thus the patients received cetuximab and reported a partial response as assessed by Computed Tomography (CT), Positron Emission Tomography (PET) and fused PET-CT after three months of therapy. Therefore, both patients are still on therapy. This preliminary experience suggests that cetuximab may be a useful therapeutic choice in advanced pre-treated thymic tumors.
Cetuximab is an active treatment of metastatic and chemorefractory thymoma
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(283 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote